CM336
Phase 3Small molecule
CM336 is one of 148 small molecule programs targeting Bispecific Antibody. It is currently in Phase 3.
9
Indications
11
Total Trials
11
Active Trials
147
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Empliciti
Bristol-Myers SquibbPhase 3
TALVEY
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Vepesid
AAvyxa
Phase 3
Cytosar
TevaPhase 3
Mozobil
GGenzyme, a Sanofi Company
Phase 3
Sylvant
RRECORDATI GROUP
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma (MM)2 trials
A Phase Ib/II, Non-Randomized, Biomarker-Stratified Umbrella Study of Chemotherapy-Free Strategies in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Status: Sonrotoclax and a BCMA/CD3 Bispecific Antibody (AL-005)
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07687004·50 enrolled
Amyloidosis1 trial
Bispecific Antibody1 trial
BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07407010·10 enrolled
5 more indications
Relapsed or Refractory1 trial
Immune Thrombocytopenia1 trial
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06799611·20 enrolled
POEMS syndrome1 trial
BCMA/CD3 BsAb Therapy for POEMS Syndrome
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07115654·10 enrolled
Plasma Cell Leukemia (PCL)1 trial
A Prospective, Single-Arm, Single-Center, Phase II Study Evaluating the Safety and Efficacy of CM336 in Combination With Isatuximab, Lenalidomide, and Bortezomib in Newly Diagnosed Primary Plasma Cell Leukemia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07652905·24 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CM336. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKeymed Biosciences Co.Ltd